Six-Gene PHFScore From Spain’s CRG Improves Acute Myeloid Leukemia Survival Prediction as Remission Reaches 85% in Highest PHF19 Group

InnoDexis has published its latest Innovation Intelligence Report covering acute myeloid leukemia prognosis, analyzing one innovation from Spain, published on 23 October 2026. The report reveals that researchers at the Centre for Genomic Regulation (CRG) in Barcelona developed PHFScore, a six-gene scoring system that predicts patient survival and response to chemotherapy more accurately than PHF19 alone, with remission following standard chemotherapy reaching up to 85% in patients with the highest PHF19 expression and no more than 50% in those with the lowest.

Key Findings

PHFScore combines six genes, PHF19, CARMIL1, HOPX, ALDH1A1, CALR and STAR, whose collective activity correlates strongly with patient outcomes and treatment response in acute myeloid leukemia (AML). It improves prognostic accuracy compared with PHF19 alone, which is the central result of the study.

Remission rates following standard chemotherapy differed sharply by PHF19 expression. Patients with the highest expression reached up to 85% remission, while those with the lowest reached no more than 50%. PHF19 alone already says something about how patients will fare, and combining it with five other genes adds more accurate prognostic information.

The score was built by cross-analyzing mouse model experiments with human patient datasets over a five-year study. Iterative cross-validation between gene-knockout mouse models and human AML datasets isolated persistent markers. The mice and patients were at very different stages of the disease, yet the molecular data pointed in the same direction, which strengthens the model.

Measuring six genes is simpler and cheaper than reading a broader genetic profile, and it can be done on bone marrow samples that are already routinely collected. Targeted gene expression platforms such as qPCR are widely available in clinical pathology laboratories.

Several of the six genes had not been described in leukemia or in how blood forms, and their functions are not yet known. The study therefore also identifies candidate therapeutic targets. The work remains preclinical, and commercial readiness is rated low.

Strategic Insight and Trend Analysis

The dominant trend in this research is a shift in oncology diagnostics from broad genomic profiling toward validated low-gene signatures that can be implemented quickly and economically. Current AML risk stratification often relies on extensive, expensive genetic profiling. PHFScore offers a focused alternative that keeps strong predictive value, tied directly to cellular differentiation states rather than to a broad gene panel.

The biology explains why the score works. Blood cells form a hierarchy, with plastic stem cells at the top and mature cells with fixed identities below. The more a cancer holds on to that plasticity, the more malignant it tends to be, and the six genes capture that stem-cell plasticity and differentiation state, which is used to predict chemoresistance. How the loss of PHF19 keeps cancer cells in an immature, plastic state is still an open question.

The evidence has clear limits. The score was validated in mouse models and retrospective human cohort data, and retrospective findings may vary in broader, heterogeneous real-world patient populations. Prospective clinical validation is required before a diagnostic assay can be deployed, and routine clinical diagnostic use is 5 to 10 years away. Approval as an in vitro diagnostic from authorities such as the EMA or FDA will also be needed.

Competition from existing comprehensive next-generation sequencing platforms and reluctance among clinical laboratories to adopt new gene panels without formal approvals and guidelines remain the main market barriers. The strategic question is whether a cheaper six-gene test can be validated before those barriers harden.

Global and Industry Implications

For corporates and R&D teams, PHFScore can be transferred to diagnostic assay manufacturers and pharmaceutical companies through licensing or diagnostic kit development. It also points to drug discovery targeting CARMIL1, HOPX, ALDH1A1, CALR, STAR or PHF19, and it informs broader oncology research into cell plasticity and chemoresistance. For diagnostics teams, the practical appeal is a targeted gene expression score that standard laboratory equipment can run.

For investors and capital allocators, PHFScore presents a licensing opportunity for molecular diagnostic firms seeking low-cost, high-accuracy cancer stratification tools. The position is early: commercial readiness is low, funding is needed for longitudinal prospective clinical validation, and the path to routine use is 5 to 10 years.

For policymakers and national innovation bodies, the main requirements are regulatory approval for an in vitro diagnostic test and clinical guidelines that allow laboratories to adopt new gene panels. Clinical partners for prospective validation in larger AML patient cohorts are the stated collaboration need, and prospective funding is the gap to close.

InnoDexis Statement

“A six-gene signature built on stem-cell plasticity shifts leukemia prognosis from broad genomic profiling toward focused, low-cost measurement, and prospective clinical validation is the step that decides whether it reaches routine diagnostics,” noted InnoDexis in its latest intelligence report.

Conclusion

The next milestones to watch are prospective clinical trials that validate PHFScore in routine clinical workflows, functional characterization of the newly identified blood cancer genes, and clinical partnerships for larger AML patient cohorts. Regulatory approval as an in vitro diagnostic remains the gate to adoption, with routine use estimated at 5 to 10 years. InnoDexis will continue to track oncology diagnostics, precision medicine and single-cell genomics as this field develops. The complete Acute Myeloid Leukemia Prognosis Innovation Intelligence Report is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.